share_log

Jilin Jian Yisheng Pharmaceutical's (SZSE:002566) Solid Earnings May Rest On Weak Foundations

Jilin Jian Yisheng Pharmaceutical's (SZSE:002566) Solid Earnings May Rest On Weak Foundations

吉林健益生藥業(深圳證券交易所:002566)的穩健收益可能建立在基礎薄弱的基礎上
Simply Wall St ·  05/02 18:17

Jilin Jian Yisheng Pharmaceutical Co., Ltd.'s (SZSE:002566) healthy profit numbers didn't contain any surprises for investors. We believe that shareholders have noticed some concerning factors beyond the statutory profit numbers.

吉林健益生藥業有限公司s(SZSE:002566)健康的利潤數字並沒有讓投資者感到意外。我們認爲,股東們已經注意到法定利潤數字之外的一些令人擔憂的因素。

earnings-and-revenue-history
SZSE:002566 Earnings and Revenue History May 2nd 2024
SZSE: 002566 收益和收入歷史記錄 2024 年 5 月 2 日

The Impact Of Unusual Items On Profit

不尋常物品對利潤的影響

Importantly, our data indicates that Jilin Jian Yisheng Pharmaceutical's profit received a boost of CN¥20m in unusual items, over the last year. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. We can see that Jilin Jian Yisheng Pharmaceutical's positive unusual items were quite significant relative to its profit in the year to March 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

重要的是,我們的數據表明,去年吉林健益生製藥的不尋常項目利潤增加了2000萬元人民幣。雖然獲得更高的利潤總是件好事,但來自不尋常物品的巨額捐款有時會抑制我們的熱情。當我們分析全球絕大多數上市公司時,我們發現重大不尋常的事項往往不會重演。這正如你所預料的那樣,因爲這些增強被描述爲 “不尋常”。我們可以看到,截至2024年3月的一年中,吉林健益生藥業的正面異常項目與其利潤相比相當可觀。在其他條件相同的情況下,這可能會使法定利潤成爲衡量潛在盈利能力的不良指導。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Jilin Jian Yisheng Pharmaceutical.

注意:我們始終建議投資者檢查資產負債表的實力。點擊此處查看我們對吉林健益生製藥的資產負債表分析。

Our Take On Jilin Jian Yisheng Pharmaceutical's Profit Performance

我們對吉林健益生製藥盈利表現的看法

As we discussed above, we think the significant positive unusual item makes Jilin Jian Yisheng Pharmaceutical's earnings a poor guide to its underlying profitability. For this reason, we think that Jilin Jian Yisheng Pharmaceutical's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. And we are pleased to note that EPS is at least heading in the right direction in the alst twelve months. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you'd like to know more about Jilin Jian Yisheng Pharmaceutical as a business, it's important to be aware of any risks it's facing. Every company has risks, and we've spotted 2 warning signs for Jilin Jian Yisheng Pharmaceutical you should know about.

正如我們上面討論的那樣,我們認爲這一重大利好不尋常的項目使吉林健益生製藥的收益無法衡量其潛在盈利能力。出於這個原因,我們認爲吉林健益生藥業的法定利潤可能不利於其潛在盈利能力,並可能給投資者留下過於積極的公司印象。我們高興地注意到,在過去的十二個月中,每股收益至少朝着正確的方向發展。當然,我們只是在分析其收益時才浮出水面;人們還可以考慮利潤率、預測增長和投資回報率等因素。如果您想進一步了解吉林健益生藥業作爲一家企業,請務必了解其面臨的任何風險。每家公司都有風險,我們發現了吉林健益生製藥的兩個警示信號,你應該知道。

Today we've zoomed in on a single data point to better understand the nature of Jilin Jian Yisheng Pharmaceutical's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

今天,我們放大了單一數據點,以更好地了解吉林健益生製藥利潤的性質。但是,如果你能夠將注意力集中在細節上,總會有更多的事情需要發現。有些人認爲高股本回報率是優質業務的好兆頭。因此,你可能希望看到這份免費收藏的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論